RGX-202
Gene therapy / editing
Evidence outlook · registrational
Duchenne Muscular Dystrophy: topline reported 2026-05-14
No completed mid-stage readout is on record. The sponsor reported topline results on 2026-05-14 (RGX-202 pivotal AFFINITY DUCHENNE Phase 3 topline: primary endpoint met). The announcement is listed under Regulatory events.
Company guidance: regulatory filing expected next year (REGENXBIO Inc., 5 Nov 2026). “We also remain on track for the RGX-202 BLA submission early next year as we work toward delivering this important therapy to Duchenne patients as quickly as possible.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05693142 NCT05693142 · Duchenne Muscular Dystrophy Registry: NCT05693142 | 2/3 | Part 1 Safety measured by incidence of Adverse Events and Serious Adverse Events (52 weeks); Part 2 and 3 Pharmacodynamic (12 weeks) 2026-09 | Pivotal AFFINITY DUCHENNE (non-randomized): significant microdystrophin expression, the pharmacodynamic primary (REGENXBIO topline, 2026-05-14). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2/3 (1)
What this study did
Phase 2 (1)
What this study did
Competitive landscape
This drug's own stage for Duchenne Muscular Dystrophy: Phase 2/3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| RGX-202: this drug | Phase 2/3 | Gene therapy / editing | Dystrophin (microdystrophin transgene) | not yet graded | No reviewed efficacy summary in this indication | |
| Givinostat | Approved | Small molecule | HDAC | Reliable signal | NCT02851797: Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment (Baseline and 18 months): Givinostat 1.27 seconds (Standard Error 0.04) | Placebo 1.48 seconds (Standard Error 0.058) | |
| Deramiocel | Phase 3 | Cell therapy | Cardiac cell therapy | not yet graded | No reviewed efficacy summary in this indication | |
| Delpacibart Zotadirsen | Phase 2 | RNA / oligonucleotide | DMD exon 44 | not yet graded | No reviewed efficacy summary in this indication | |
| Bampidirsen | Phase 1/2 | RNA / oligonucleotide | DMD exon 53 | not yet graded | No reviewed efficacy summary in this indication | |
| Nivudirsen (BMN 351) | Phase 1/2 | RNA / oligonucleotide | DMD exon 51 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent